Interpretable LightGBM model with SHAP analysis predicts non‐excellent response to initial radioiodine therapy in differentiated thyroid carcinoma
The developed LightGBM framework precisely predicts primary <sup>1</sup> <sup>3</sup> <sup>1</sup>I therapeutic efficacy in DTC patients, with SHAP-driven elucidation of clinical risk factor contributions enabling personalized therapeutic paradigms.Future integration of multicenter prospective data and molecular biomarkers is required to enhance model generalizability.
Authors
- Qing Zhang
- Yangyang Lei
- Zhaoxia Luo
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Journal of Applied Clinical Medical Physics
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1002/acm2.70555
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00